Clinical trials
Amyotrophic Lateral Sclerosis trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
54 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 9 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 9 |
| 2025 | 9 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 18 |
| Recruiting | 13 |
| Completed | 9 |
| Not yet recruiting | 5 |
| Active, not recruiting | 5 |
| Enrolling by invitation | 3 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peking University Third Hospital | 20 |
| Beijing Tiantan Hospital | 3 |
| Peking University | 2 |
| RJK Biopharma Ltd | 2 |
| Ruijin Hospital | 2 |
| Xuanwu Hospital, Beijing | 2 |
| Biogen | 1 |
| ChaodongWang | 1 |
| Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. | 1 |
| Dongzhimen Hospital, Beijing | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amyotrophic Lateral Sclerosis | 54 |
| Motor Neuron Disease | 4 |
| Neurodegenerative Diseases | 2 |
| Alzheimer Disease | 1 |
| Brain Stem Infarctions | 1 |
| Frailty | 1 |
| Frontotemporal Dementia | 1 |
| Inflammation | 1 |
| Lewy Body Disease | 1 |
| Multiple System Atrophy | 1 |
Trials
Showing 1 to 25 of 54. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.